Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.42 |
| ▸ | FEN1 | P39748 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 11/20 | 0.41 |
| ▸ | HTR2B | P41595 | 8/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693134 | 0.92 | ALOX5AP (0.44) | ALOX5APFEN1HTR2CHTR2BHTR2A | |
| SCHEMBL2572492 | 0.85 | HTR2C (0.47) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL2015068 | 0.85 | HTR2C (0.47) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL2013148 | 0.83 | HTR2C (0.40) | HTR2CHTR2BHTR2AHTR6PDE3B | |
| SCHEMBL2018378 | 0.83 | HTR2C (0.48) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL2591154 | 0.83 | HTR2C (0.48) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL2015683 | 0.83 | HTR2C (0.45) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL2019545 | 0.83 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL2015749 | 0.82 | HTR2C (0.41) | HTR2CHTR2BHTR2APDE3BPDE3A | |
| SCHEMBL2013664 | 0.81 | HTR2C (0.49) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | claimed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | claimed |
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8546377-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | ALOX5AP 862/4885FEN1 4467/4885HTR2C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.